In the NEURO-TTR trial, three cases (3%) of severe thrombocytopenia, including one in association with a fatal intracranial hemorrhage, were observed during therapy with inotersen, an ASO designed to inhibit hepatic production of transthyretin in patients with hereditary transthyretin amyloidosis. Here, TTR is linked to intracranial hemorrhage.